Controlled Delivery of Dutasteride Using Dissolvable Microarrays: Initial Formulation and In Vivo Evaluation

Abstract

Dutasteride is prescribed as a once-daily oral capsule for the treatment of symptomatic benign prostatic hyperplasia. As an alternative and patient-focused drug product, this laboratory evaluated the potential to deliver dutasteride in a controlled/sustained manner when formulated as a microarray. The low oral dose, low aqueous solubility, and slow rate of elimination of dutasteride were considered ideal properties which may enable a once-weekly microarray option for patients. The concept of sustained release was initially proven in mini-pigs whereby simple intradermal administration of a nanomilled dutasteride suspension (0.12 mg/kg) was associated with an exposure period of at least 1 month. Dissolvable microarrays were successfully manufactured using a nanomilled suspension and were administered to rats at doses up to 0.32 mg/kg. In these studies, serum dutasteride was quantifiable for approximately 2 weeks after a single application. In silico modeling of the rat data using a two-compartment intradermal model was conducted and predicted that, in humans, a once-weekly dose of 2 mg, given as a microarray, could deliver cumulative and therapeutically relevant levels of dutasteride in a manner which is comparable to that observed with the current oral regimen.

Keywords: controlled delivery; dutasteride; intradermal; microarray(s); nanoparticles; pharmacokinetics.